This is the first update to the original CTS communication distributed on July 6th. As previously communicated, all CTS healthcare partners will remain on the Grifols ZIKV clinical trial until at least the end of October 2018, which coincides with the end of the WNV season.
Check out the Communication page for the complete details on the NAT ZIKV test update or by clicking the link: Communications
The CTS forms listed below have been revised with an implementation date of September 2, 2019. ...
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...
As the US coast prepares for Hurricane Florence to make landfall, we have received importan...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...